Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation to autologous enriched T-cells genetically modified with a retroviral vector to express two chimeric antigen receptors targeting CD19 and CD22 (AUTO3) for the treatment of acute lymphoblastic leukemia (ALL).
{iframe}https://www.globenewswire.com/news-release/2019/04/23/1807803/0/en/Autolus-Therapeutics-Receives-FDA-Orphan-Drug-Designation-for-AUTO3-for-Treatment-of-Acute-Lymphoblastic-Leukemia.html{/iframe}